% | $
Quotes you view appear here for quick access.

Arena Pharmaceuticals, Inc. Message Board

nimachr 1 post  |  Last Activity: Jul 15, 2015 10:46 AM Member since: Mar 25, 2004
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to


    by mistarichter Jul 15, 2015 8:26 AM
    nimachr nimachr Jul 15, 2015 10:46 AM Flag

    This could be the reason is up today... from seeking alpha

    Celgene's (CELG +9.5%) $7.2B deal for Receptos (RCPT +10.3%) is “a great acquisition at a great price," Nomura analysts say, as ozanimod could enable CELG's inflammation and immunology franchise to double peak sales to $10B and reduce reliance on Revlimid to drive future growth, and the acquisition price of less than 2x peak sales is a steep discount relative to recent comparisons.Wedbush analyst Liana Moussatos sees plenty of potential upside to justify a rival bidder stepping in for RCPT, noting that she had estimated the company could be valued at $348/share, or ~$10.9B, in a buyout, substantially more than CELG's $232 offer.The deal is boosting some biotech names (IBB +1.9%), including PTC Therapeutics (PTCT +11.7%), Celsion (CLSN +7.1%) and Arena Pharmaceuticals (ARNA +6.7%).

2.26Oct 12 4:00 PMEDT